SCHEMBL4628958

SCHEMBL4628958

CC(C)c1ccccc1N=C(N)NC(=O)c1ccccc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 5/20 0.82
SCN5A Q14524 3/20 0.82
SIGMAR1 Q99720 4/20 0.57
GRIN2D O15399 1/20 0.57
GRIN3B O60391 1/20 0.57
GRIN1 Q05586 1/20 0.57
GRIN2A Q12879 1/20 0.57
GRIN2B Q13224 1/20 0.57
GRIN2C Q14957 1/20 0.57
GRIN3A Q8TCU5 1/20 0.57
CYP1A2 P05177 1/20 0.53
LMNA P02545 2/20 0.50
KMT2A Q03164 1/20 0.50
TPH1 P17752 1/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NOS3 P29474 2/20 0.47
NOS1 P29475 2/20 0.47
NOS2 P35228 2/20 0.47
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4628748 0.91 SCN2A (1.00) SCN2ASCN5ASIGMAR1GRIN2DGRIN3B
SCHEMBL4628571 0.85 SCN2A (0.72) SCN2ASCN5ASIGMAR1GRIN2DGRIN3B
SCHEMBL4628716 0.82 SCN2A (0.69) SCN2ASCN5ASIGMAR1GRIN2DGRIN3B
SCHEMBL4628998 0.82 SCN2A (0.68) SCN2ASCN5ASIGMAR1GRIN2DGRIN3B
SCHEMBL4627567 0.81 SCN5A (0.64) SCN2ASCN5ASIGMAR1GRIN2DGRIN3B
SCHEMBL4629404 0.81 SCN2A (0.64) SCN2ASCN5ASIGMAR1GRIN2DGRIN3B
SCHEMBL4629406 0.77 SCN2A (0.78) SCN2ASCN5ASIGMAR1GRIN2DGRIN3B
SCHEMBL6721281 0.73 SIGMAR1 (1.00) SCN2ASCN5ASIGMAR1GRIN2DGRIN3B
SCHEMBL19136081 0.73 SIGMAR1 (1.00) SCN2ASCN5ASIGMAR1GRIN2DGRIN3B
SCHEMBL6137816 0.72 SIGMAR1 (0.62) SCN2ASCN5ASIGMAR1GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SCN2A 1613/4885SCN5A 1196/4885SIGMAR1 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.